Key takeaways
- Bull case: Third-quarter revenue rose 36.3% to $5.12 billion, and non-GAAP EPS beat the $16.19 consensus by 23.93%.
- Dividend safety: Amgen paid out about 58% of its trailing GAAP earnings, based on $9.94 in dividends per share against $17.25 in EPS.
- Free cash flow was $3.654 billion for the quarter, which is more than double the roughly $1.36 billion it costs to pay the dividend on every outstanding share.
Biotech usually torches cash and dilutes shareholders to fund the next trial. Three drugmakers flip that script, and the one with the smallest yield may be hiding the sturdiest payout of all.
See the latest quote, chart and news for AMGN.
